Updated with new company comment.
Earlier Tuesday, Radient issued a statement accusing TheStreet of publishing an "inaccurate" story about the involvement of the Mayo Clinic in a clinical study of Radient's cancer-screening test Onko-Sure.
Radient's stock was halted Monday just before 12 p.m. ET by the New York Stock Exchange with shares at 41 cents. The stock remained halted for most of Tuesday, opening at 3:31 pm ET up 9 cents to 51 cents a share.TheStreet published a story Monday in which Mayo Clinic denied Radient's claim that Mayo was working with Radient on a new clinical validation study of the Onko-Sure cancer test. "Mayo is not engaged in clinical studies with Radient and does not have a partnership agreement with Radient," said Mayo Clinic spokesperson Kathy Anderson in a statement emailed to TheStreet Friday. Mayo Clinic's statement contradicts Radient's recent pronouncements regarding the pending release of results from a new clinical validation study of Onko-Sure. In a press release issued Jan. 18, Radient said it was making "progress on its clinical study with Mayo Clinic for the validation of the company's US FDA-cleared Onko-Sure" test. The same Radient press release described the Onko-Sure clinical study as one in which "1,000 colorectal patient samples with various disease stages are being tested in parallel by RPC